APA (7th ed.) Citation

Barnum, C. J., Chen, X., Chung, J., Chang, J., Williams, M., Grigoryan, N., . . . Tansey, M. G. (2014). Peripheral Administration of the Selective Inhibitor of Soluble Tumor Necrosis Factor (TNF) XPro®1595 Attenuates Nigral Cell Loss and Glial Activation in 6-OHDA Hemiparkinsonian Rats. Journal of Parkinson's Disease, 4(3), 349. https://doi.org/10.3233/JPD-140410

Chicago Style (17th ed.) Citation

Barnum, Christopher J., Xi Chen, Jaegwon Chung, Jianjun Chang, Martha Williams, Nelly Grigoryan, Raymond J. Tesi, and Malú G. Tansey. "Peripheral Administration of the Selective Inhibitor of Soluble Tumor Necrosis Factor (TNF) XPro®1595 Attenuates Nigral Cell Loss and Glial Activation in 6-OHDA Hemiparkinsonian Rats." Journal of Parkinson's Disease 4, no. 3 (2014): 349. https://doi.org/10.3233/JPD-140410.

MLA (9th ed.) Citation

Barnum, Christopher J., et al. "Peripheral Administration of the Selective Inhibitor of Soluble Tumor Necrosis Factor (TNF) XPro®1595 Attenuates Nigral Cell Loss and Glial Activation in 6-OHDA Hemiparkinsonian Rats." Journal of Parkinson's Disease, vol. 4, no. 3, 2014, p. 349, https://doi.org/10.3233/JPD-140410.